Phase 3 double-blind placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection (EVOGUARD)
Study of Vaginal Gel (EVO100) in Prevention of Chlamydia and Gonorrhea (Ages 18-24)
Sponsor: Evofem, Inc.
Enrolling: Female Patients Only
IRB Number: AAAT8029
U.S. Govt. ID: NCT04553068
Contact: Argelia Arias: 212-305-9672 / aa4153@cumc.columbia.edu
Additional Study Information: Protocol is looking to evaluate efficacy of the EVO100 vaginal gel in the prevention of urogenital Chlamydia Trachomatis (CT) and Neisseria gonorrhoeae (GC) infections. You may be eligible if you are between the ages of 18 years or older with a CT and/or GC infectiondiagnosis within the last 16 weeks.
This study is closed
Investigator
Paula Castano, MD, MPH
Do You Qualify?
Are you between the ages of 18-24? Yes No
Have you been diagnosed and treated for chlamydia and/or gonorrhea within the last 16 weeks? Yes No
Are you currently pregnant? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Argelia Arias
aa4153@cumc.columbia.edu
212-305-9672
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE